EGLN3 and glioblastoma: Consistent with these findings, MAEA-mediated ubiquitination and degradation of PHD3 has been shown to facilitate glioblastoma progression and confer resistance to temozolomide treatment, highlighting its role in chemoresistance mechanisms in this context (53).